Ming-Ming Zhou
University of Virginia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ming-Ming Zhou.
Molecular and Cellular Biology | 1997
Kodimangalam S. Ravichandran; Ming-Ming Zhou; Joanne C. Pratt; John E. Harlan; Scott F. Walk; Stephen W. Fesik; Steven J. Burakoff
The adapter protein Shc is a critical component of mitogenic signaling pathways initiated by a number of receptors. Shc can directly bind to several tyrosine-phosphorylated receptors through its phosphotyrosine-binding (PTB) domain, and a role for the PTB domain in phosphotyrosine-mediated signaling has been well documented. The structure of the Shc PTB domain demonstrated a striking homology to the structures of pleckstrin homology domains, which suggested acidic phospholipids as a second ligand for the Shc PTB domain. Here we demonstrate that Shc binding via its PTB domain to acidic phospholipids is as critical as binding to phosphotyrosine for leading to Shc phosphorylation. Through structure-based, targeted mutagenesis of the Shc PTB domain, we first identified the residues within the PTB domain critical for phospholipid binding in vitro. In vivo, the PTB domain was essential for localization of Shc to the membrane, as mutant Shc proteins that failed to interact with phospholipids in vitro also failed to localize to the membrane. We also observed that PTB domain-dependent targeting to the membrane preceded the PTB domains interaction with the tyrosine-phosphorylated receptor and that both events were essential for tyrosine phosphorylation of Shc following receptor activation. Thus, Shc, through its interaction with two different ligands, is able to accomplish both membrane localization and binding to the activated receptor via a single PTB domain.
Bioorganic & Medicinal Chemistry Letters | 1999
Philip J. Hajduk; Ming-Ming Zhou; Stephen W. Fesik
Using an NMR-based screen, a series of novel phosphotyrosine mimetics were discovered that bind to the SH2 domain of Lck. These compounds may serve as useful leads for the design of nonpeptide inhibitors of SH2 domains with improved bioavailability and metabolic stability compared to the natural ligands that contain phosphotyrosine.
Nature | 1995
Ming-Ming Zhou; Kodimangalam S. Ravichandran; Edward T. Olejniczak; Andrew M. Petros; Robert P. Meadows; Michael Sattler; John E. Harlan; Warren S. Wade; Steven J. Burakoff; Stephen W. Fesik
Biochemistry | 1997
Zhang M; Ming-Ming Zhou; R. L. Van Etten; Cynthia V. Stauffacher
Nature Structural & Molecular Biology | 1996
Ming-Ming Zhou; Baohua Huang; Edward T. Olejniczak; Robert P. Meadows; Suzanne B. Shuker; Masaya Miyazaki; Thomas Trüb; Steven E. Shoelson; Stephen W. Fesik
Journal of Biological Chemistry | 1992
K. Ostanin; Etti Harms; P. Stevis; R. Kuciel; Ming-Ming Zhou; R. L. Van Etten
Journal of Biological Chemistry | 1994
Jeffrey P. Davis; Ming-Ming Zhou; R. L. Van Etten
Journal of Biological Chemistry | 1996
Ming-Ming Zhou; John E. Harlan; Warren S. Wade; Seth Crosby; Kodimangalam S. Ravichandran; Steven J. Burakoff; Stephen W. Fesik
Proceedings of the National Academy of Sciences of the United States of America | 1995
Ming-Ming Zhou; Robert P. Meadows; Timothy M. Logan; Ho Sup Yoon; Warren S. Wade; Kodimangalam S. Ravichandran; Steven J. Burakoff; Stephen W. Fesik
Biochemistry | 1997
Edward T. Olejniczak; Ming-Ming Zhou; Stephen W. Fesik